• EMA accepted Almirall’s filing to extend Ebglyss (lebrikizumab) to moderate-to-severe atopic dermatitis in children aged 6 months to under 18 years.
• Application covers patients weighing under 40 kg; supported by interim data from Phase III ADorable-1 and ADorable-2 extension studies.
• Almirall holds European rights for lebrikizumab; Eli Lilly retains rights in the US and outside Europe.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Almirall SA published the original content used to generate this news brief via Business Wire (Ref. ID: 202607200400BIZWIRE_USPR_____20260720_BW632317) on July 20, 2026, and is solely responsible for the information contained therein.